Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Sees Large Drop in Short Interest

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the recipient of a large decrease in short interest in March. As of March 31st, there was short interest totalling 53,600 shares, a decrease of 53.2% from the March 15th total of 114,600 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily volume of 325,600 shares, the short-interest ratio is currently 0.2 days.

Chugai Pharmaceutical Trading Up 20.8 %

Shares of Chugai Pharmaceutical stock traded up $4.97 during trading on Friday, reaching $28.88. The stock had a trading volume of 366,799 shares, compared to its average volume of 225,471. The company has a market capitalization of $95.04 billion, a price-to-earnings ratio of 37.51 and a beta of 0.80. Chugai Pharmaceutical has a 52 week low of $14.52 and a 52 week high of $30.37. The stock has a fifty day moving average price of $23.62 and a two-hundred day moving average price of $22.79.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.18 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a return on equity of 21.53%. On average, equities analysts forecast that Chugai Pharmaceutical will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.